Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.
about
A systematic review of observational studies evaluating costs of adverse drug reactionsUse of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung CancerEconomic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study.Risk assessment of drug interaction potential and concomitant dosing pattern on targeted toxicities in pediatric cancer patients.Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review.Treatment-associated toxicities reported by patients with early-stage invasive breast cancer.Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.The eSMART study protocol: a randomised controlled trial to evaluate electronic symptom management using the advanced symptom management system (ASyMS) remote technology for patients with cancer.The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care--an observational analysis on non-small-cell lung cancer patients.Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.
P2860
Q28079380-E7406BE2-35A6-40B8-90F4-5BF6541B1ECDQ36073707-04713877-73CA-4BD0-BDC1-0DA9F872EDB4Q36220882-63614EB8-433E-401C-8923-C576886A95FCQ36857824-BE4BD6E2-BA32-4CA7-BD9F-E7F388BFBC7EQ36951924-54C7CC4F-3D96-4034-8708-7FEF0C8F1EB2Q38129733-FED1A86F-4FD2-492B-A793-843DF7F8244FQ39002082-B7A7C8E7-41BD-4C2C-8824-B6B4094CD05DQ40305101-D7D756A1-4E4D-485A-8A27-488846E5F67AQ43571500-75152D1B-E2D6-461A-857F-7E0046165ADCQ46027938-24CCC27A-915C-4285-A76F-D6E099298D81Q46039744-8FCA6402-E719-40E3-90BF-E7F8B781C86CQ47908189-78A927A0-D90E-48BD-BC80-954D0002CA14Q48537667-94321A09-C93C-455D-BE5F-2677B1D24966
P2860
Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Health resource consumption an ...... e disorder and NSCLC patients.
@en
Health resource consumption an ...... e disorder and NSCLC patients.
@nl
type
label
Health resource consumption an ...... e disorder and NSCLC patients.
@en
Health resource consumption an ...... e disorder and NSCLC patients.
@nl
prefLabel
Health resource consumption an ...... e disorder and NSCLC patients.
@en
Health resource consumption an ...... e disorder and NSCLC patients.
@nl
P2093
P2860
P356
P1433
P1476
Health resource consumption an ...... ve disorder and NSCLC patients
@en
P2093
A Ihbe-Heffinger
B J Paessens
C Müller-Thomas
C von Schilling
P2860
P304
P356
10.1093/ANNONC/MDQ759
P50
P577
2011-02-22T00:00:00Z